JP2024071393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024071393A5 JP2024071393A5 JP2024030027A JP2024030027A JP2024071393A5 JP 2024071393 A5 JP2024071393 A5 JP 2024071393A5 JP 2024030027 A JP2024030027 A JP 2024030027A JP 2024030027 A JP2024030027 A JP 2024030027A JP 2024071393 A5 JP2024071393 A5 JP 2024071393A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- use according
- antibody
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2024097 | 2019-10-24 | ||
| NL2024097 | 2019-10-24 | ||
| JP2022523992A JP7532514B2 (ja) | 2019-10-24 | 2020-10-23 | Ｈｅｒ２及びｈｅｒ３陽性癌に罹患している対象を治療するための手段及び方法 |
| PCT/NL2020/050656 WO2021080428A1 (en) | 2019-10-24 | 2020-10-23 | Means and methods for treating subjects with her2 and her3 positive cancer |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022523992A Division JP7532514B2 (ja) | 2019-10-24 | 2020-10-23 | Ｈｅｒ２及びｈｅｒ３陽性癌に罹患している対象を治療するための手段及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024071393A JP2024071393A (ja) | 2024-05-24 |
| JP2024071393A5 true JP2024071393A5 (enExample) | 2024-11-12 |
| JP7678175B2 JP7678175B2 (ja) | 2025-05-15 |
Family
ID=68807359
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022523992A Active JP7532514B2 (ja) | 2019-10-24 | 2020-10-23 | Ｈｅｒ２及びｈｅｒ３陽性癌に罹患している対象を治療するための手段及び方法 |
| JP2024030027A Active JP7678175B2 (ja) | 2019-10-24 | 2024-02-29 | Ｈｅｒ２及びｈｅｒ３陽性癌に罹患している対象を治療するための手段及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022523992A Active JP7532514B2 (ja) | 2019-10-24 | 2020-10-23 | Ｈｅｒ２及びｈｅｒ３陽性癌に罹患している対象を治療するための手段及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220372166A1 (enExample) |
| EP (1) | EP4048702A1 (enExample) |
| JP (2) | JP7532514B2 (enExample) |
| KR (1) | KR20220103954A (enExample) |
| CN (2) | CN116327919A (enExample) |
| AU (1) | AU2020371040B2 (enExample) |
| CA (1) | CA3158609A1 (enExample) |
| TW (1) | TWI873210B (enExample) |
| WO (1) | WO2021080428A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3600411A1 (en) * | 2017-03-31 | 2020-02-05 | Merus N.V. | Antibodies for the treatment of erbb-2/erbb-3 positive tumors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013022887A2 (pt) * | 2011-03-15 | 2016-12-06 | Merrimack Pharmaceuticals Inc | superação de resistência a inibidores de via de erbb |
| CN120383672A (zh) | 2012-04-20 | 2025-07-29 | 美勒斯公司 | 用于产生免疫球蛋白样分子的方法和手段 |
| US20150203591A1 (en) * | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| IL301147A (en) * | 2014-02-28 | 2023-05-01 | Merus Nv | An antibody that binds to ErbB-2 and ErbB-3 |
| EP3110846B1 (en) * | 2014-02-28 | 2020-08-19 | Merus N.V. | Antibodies that bind egfr and erbb3 |
| US20210206875A1 (en) * | 2017-03-31 | 2021-07-08 | Merus N.V. | Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour |
| CN110650752A (zh) * | 2017-03-31 | 2020-01-03 | 美勒斯公司 | 用于治疗具有NRG1融合基因的细胞的ErbB-2和ErbB3结合双特异性抗体 |
| EA201992522A1 (ru) * | 2017-05-17 | 2020-04-22 | Мерус Н.В. | КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ |
| WO2022098233A1 (en) * | 2020-11-04 | 2022-05-12 | Merus N.V. | Means and methods for treating subjects with erbb3 mutation positive cancer |
-
2020
- 2020-10-23 EP EP20801415.9A patent/EP4048702A1/en active Pending
- 2020-10-23 AU AU2020371040A patent/AU2020371040B2/en active Active
- 2020-10-23 CN CN202211199242.9A patent/CN116327919A/zh active Pending
- 2020-10-23 WO PCT/NL2020/050656 patent/WO2021080428A1/en not_active Ceased
- 2020-10-23 CA CA3158609A patent/CA3158609A1/en active Pending
- 2020-10-23 US US17/755,196 patent/US20220372166A1/en active Pending
- 2020-10-23 KR KR1020227016799A patent/KR20220103954A/ko active Pending
- 2020-10-23 JP JP2022523992A patent/JP7532514B2/ja active Active
- 2020-10-23 CN CN202080083392.6A patent/CN114761436A/zh active Pending
- 2020-10-23 TW TW109136884A patent/TWI873210B/zh active
-
2024
- 2024-02-29 JP JP2024030027A patent/JP7678175B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Parakh et al. | Evolution of anti-HER2 therapies for cancer treatment | |
| Kumar et al. | Chemotherapy and targeted therapy in the management of cervical cancer | |
| Henricks et al. | The use of combinations of monoclonal antibodies in clinical oncology | |
| Bonomi | Erlotinib: a new therapeutic approach for non-small cell lung cancer | |
| Ayyappan et al. | Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer | |
| US20150231238A1 (en) | Overcoming resistance to erbb pathway inhibitors | |
| Van de Wiel et al. | Neoadjuvant systemic therapy in breast cancer: Challenges and uncertainties | |
| JP2008531576A5 (enExample) | ||
| CN102223897A (zh) | 抗-vegf抗体与化学治疗联合用于治疗乳腺癌的应用 | |
| Lyons et al. | Systemic therapy for esophagogastric cancer: targeted therapies | |
| Giaccone | HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy | |
| Satolli et al. | Gastric cancer: The times they are a-changin’ | |
| Woo et al. | Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer | |
| JPWO2022270524A5 (enExample) | ||
| Mehta et al. | Targeting RTKs/nRTKs as promising therapeutic strategies for the treatment of triple-negative breast cancer: evidence from clinical trials | |
| JP2024071393A5 (enExample) | ||
| Kordes et al. | Targeted therapy for advanced esophagogastric adenocarcinoma | |
| Rapidis et al. | Targeted therapies in head and neck cancer: past, present and future | |
| Orditura et al. | Preoperative treatment of locally advanced esophageal carcinoma | |
| Rossi et al. | Cetuximab in advanced non-small cell lung cancer | |
| Dreanic et al. | Gastric carcinoma at the era of targeted therapies | |
| Li et al. | Current status of anti-EGFR agents | |
| Cole | Duligotuzumab. Human anti-EGFR/anti-HER3 MAb, colorectal cancer therapy, head and neck cancer therapy | |
| Nabholtz et al. | Docetaxel/trastuzumab combination therapy for the treatment of breast cancer | |
| Liu et al. | Leveraging HER2-targeted biparatopic antibodies in solid tumors |